Navigation Links
MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
Date:3/13/2008

VANCOUVER and SAN DIEGO, March 13 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, reports financial results for the three and nine months ended January 31, 2008 and an update on its programs.

Jim DeMesa, M.D., President & CEO of MIGENIX stated, "With the conclusion of our third fiscal quarter and now being halfway through our fourth quarter, we are looking forward to the completion of enrollment in the Phase III Omigard registration trial for preventing catheter-related infections being conducted by our partner, Cadence Pharmaceuticals. With completion of this trial, we expect to enter into a very important time of clinical results over the next half of the year (with both Omigard and celgosivir, our Phase II hepatitis C drug candidate) followed by our potential entry into the regulatory approval process in 2009 with Omigard."

UPDATE ON DRUG DEVELOPMENT PROGRAMS

Omiganan 1% gel (Omigard(TM)/CPI-226/MX-226; topical cationic peptide; prevention of catheter-related infections): A pivotal Phase III study being conducted by our development and commercialization partner Cadence Pharmaceuticals is in progress in the United States under a Special Protocol Assessment (SPA) agreement with the US FDA and in Europe. Cadence expects they will complete enrollment of the 1,850 patients planned for the trial in the second quarter of 2008, with results available in the second half of 2008. If the results of the trial are positive, Cadence expects to submit a New Drug Application ("NDA") for omiganan 1% gel in the first half of 2009. Under the terms of the agreement with Cadence, MIGENIX will receive up to US$27 million in development and commercialization milestone payments, upon the achievement of specified milestones, starting with the US and European regulatory submission process; and a double-digit royalty on net sales. MIGENIX has been and continues to be in discussions with p
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
2. MIGENIX releases CEO message #22
3. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
4. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
5. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
6. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
7. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
8. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
9. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
10. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Jan. 22. 2015  Varian Medical Systems (NYSE: VAR ... honored for its commitment to sustainability with inclusion on a ... the highest ranked healthcare equipment company among the Corporate Knights ... World Economic Forum at Davos, Switzerland . ...
(Date:12/24/2014)... SILVER SPRING, Md. , Dec. 24, 2014  United ... that Medtronic, Inc. (NYSE: MDT ) has ... and Drug Administration (FDA) for the use of Medtronic,s ... a newly developed catheter) for use with United Therapeutics, ...
(Date:12/24/2014)... 23, 2014 “Preparative & Process ... Flash), Consumables (Columns, Solvents, Buffers, Valves, Guages, Seals), ... Agriculture) - Forecasts to 2019” provides a detailed ... current market trends, and strategies impacting the preparative ...
(Date:12/24/2014)... December 23, 2014 On Friday, December ... the Omnibus and Continuing Resolution Appropriations Act of 2015, ... eligible to receive funding through the Congressionally Directed Medical ... (DoD). The Hydrocephalus Association (HA), working in conjunction with ...
Breaking Biology Technology:Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
... to Identify Host Correlates of Protection Against Tuberculosis , ... OTTAWA, ... of products for biological sample collection, stabilization and preparation, today ... South African Tuberculosis Vaccine Initiative (SATVI), has chosen Oragene-DNA for ...
... 28 Dendreon Corporation (Nasdaq: DNDN ) announced ... IMPACT study in the New England Journal of Medicine ... in overall survival compared to control in men with asymptomatic ... manuscript is published in the July 29, 2010 ...
... 28 Burrill & Company, a San Francisco -based global ... Banking and Media, is pleased to announce that Shawn Cross ... , , , ... the Merchant Banking Group,s strategic growth plan, which includes a broad and ...
Cached Biology Technology:DNA Genotek's Oragene-DNA Achieves 95% Compliance Rate in South African Tuberculosis Vaccine Initiative (SATVI) 2DNA Genotek's Oragene-DNA Achieves 95% Compliance Rate in South African Tuberculosis Vaccine Initiative (SATVI) 3New England Journal of Medicine Publishes Data from Pivotal Phase 3 PROVENGE IMPACT Study 2New England Journal of Medicine Publishes Data from Pivotal Phase 3 PROVENGE IMPACT Study 3New England Journal of Medicine Publishes Data from Pivotal Phase 3 PROVENGE IMPACT Study 4New England Journal of Medicine Publishes Data from Pivotal Phase 3 PROVENGE IMPACT Study 5New England Journal of Medicine Publishes Data from Pivotal Phase 3 PROVENGE IMPACT Study 6Shawn Cross Appointed CEO of Burrill Merchant Banking Group 2Shawn Cross Appointed CEO of Burrill Merchant Banking Group 3
(Date:12/19/2014)... 18, 2014   LaunchKey , the first decentralized mobile ... Internet of Things era, today announced the close of ... was led by Metamorphic Ventures with participation from ENIAC ... and others.  LaunchKey has raised $4 million to date, ...
(Date:12/17/2014)... 16, 2014 Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ... Chemical Sensor Market 2015-2019" report to their offering. ... One major trend upcoming in this market is the ... sensors help in recording of patient data for quick ...
(Date:12/11/2014)... WINSTON SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... A structural molecule and the cellular pump that regulates its ... ways of treating the lung infection, which is a leading ... University of Pittsburgh and the University of Iowa. Their findings ... Despite decades of research, there has been little new information ...
... key protein that regulates the biological clocks of mammals ... altering the levels of this protein can improve the ... this week,s advanced online publication of the journal ... for scientists to develop treatments for obesity and type ...
... Two researchers at Marshall University have been awarded ... the effects of omega-3 fatty acids on breast cancer ... Cancer Research Program has awarded Dr. Elaine Hardman, associate ... the Joan C. Edwards School of Medicine, and Dr. ...
Cached Biology News:Pitt/Iowa team finds cellular structural molecule can be toxic: Makes pneumonia worse 2Biologists discover biochemical link between biological clock and diabetes 2Biologists discover biochemical link between biological clock and diabetes 3Biologists discover biochemical link between biological clock and diabetes 4Marshall University researchers awarded more than $1 million for breast cancer studies 2Marshall University researchers awarded more than $1 million for breast cancer studies 3
... Workgroup solution is a highly scalable ... expression data in a workgroup or ... in over 40 leading pharmaceutical, biotechnology, ... GeneSpring Workgroup streamlines genomics research at ...
... for proteomic scale kinase profiling, quantitative ... drug discovery research built on the ... synthesis platform. These microarrays are available ... Kinase Substrate - Peptide Microarray Service. ...
... PEP-165 is an 18 amino acid synthetic peptide whose sequences ... peptide is (amino to carboxy terminus): S(21) - S - M ... D - E - A - I - D - K ... C(39). This peptide may be used for neutralization and ...
... containing peptidomimetics built on the flexible ... platform. These microarrays are available as ... Microarray Service. Custom Probe ... customer specified. Thousands of customer specified ...
Biology Products: